is retatrutide more effective than tirzepatide vs Tirzepatide: Best Triple Agonist Guide 2026 Retatrutide vs Tirzepatide: Key Differences

Retatrutide and Cardiac Rhythm Safety Dose-Dependent Heart Rate Increase With Low Incidence of Clinically Significant Arrhythmias in Phase 2 Obesity Trials Background Retatrutide (LY3437943) is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, developed for the treatment of obesity and cardiometabolic disease

They are not FDA approved and are intended for patients whose needs arent met by available commercial options

For peptide reconstitution and research applications, HPLC purity above 98% is generally considered acceptable

Dose titration represents the most important preventative strategy

Conclusion Obesity affects 1 billion people around the world

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials